ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

ANGEL ALEJANDRO M.D.

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

17,713Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 274

$1.14M Total Retail Price of All Prescriptions

Rank: 13 out of 274

2,096 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
57% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

4% of this provider’s 2,096 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

3% of this provider’s 16,436 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

60% of this provider’s prescriptions were for brand-name drugs, compared to an average of 50%.

Prescription Price

$64 was the average price of a prescription from this provider, compared to $132 among peers.

Prescriptions per Patient

8 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
SYNTHROID 3,811 3,635 10 1 2
LEVOXYL 1,462 1,383 10 2 16
METFORMIN HCL 1,182 1,044 3 3
METHIMAZOLE 987 928 10 4 19
GLIPIZIDE 816 781 10 5 18
JANUVIA 709 696 6 10
VITAL-D RX 708 679 10 7 77
LANTUS 414 363 8 7
JANUMET 378 355 9 22
VITAMIN D2 377 367 10 70
TRADJENTA 363 330 10 11 59
LANTUS SOLOSTAR 355 321 12 6
ANDROGEL 284 246 S3 10 13 64
ACTOS 247 236 14 29
ULTICARE 230 174 10 15 118
GLYBURIDE 219 204 R 16 27
CALCITRIOL 198 169 17 83
GLIMEPIRIDE 196 195 18 5
SURE COMFORT 196 172 18 49
JENTADUETO 159 154 10 20 154
HUMALOG MIX 75-25 158 127 21 26
LEVOTHYROXINE SODIUM 138 117 22 1
SENSIPAR 138 138 22 131
GLYBURIDE-METFORMIN HCL 136 136 R 24 40
CRESTOR 126 119 25 17
NOVOLOG MIX 70-30 126 119 25 31
SIMVASTATIN 116 107 27 8
METFORMIN HCL ER 114 101 28 15
ACTONEL 108 101 29 117
LOVAZA 107 93 30 46
HUMALOG 107 94 30 11
TIROSINT 106 106 10 32 183
ARMOUR THYROID 104 93 R 33 136
HUMULIN 70-30 96 96 34 43
NOVOLOG 87 74 35 13
PIOGLITAZONE HCL 83 78 R 36 85
GLIPIZIDE XL 82 76 37 88
NOVOLOG MIX 70-30 FLEXPEN 79 73 38 25
RANITIDINE HCL 79 74 38 69
GABAPENTIN 78 69 40 30
FLUTICASONE PROPIONATE 78 73 40 84
LEVEMIR 75 60 42 39
FUROSEMIDE 63 62 43 37
LYRICA 60 59 44 78
CABERGOLINE 58 44 45 180
LOSARTAN POTASSIUM 56 56 46 28
ZETIA 56 51 46 63
NOVOLOG FLEXPEN 55 34 48 12
PROPYLTHIOURACIL 53 53 49 151
PRANDIN 52 52 50 76
HYDROCHLOROTHIAZIDE 50 47 51 35
LEVEMIR FLEXPEN 50 48 51 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 2, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.